LuciLorla 100 mg Tablet

Description

LuciLorla 100 mg Tablet is a prescription anti-cancer medicine containing Lorlatinib 100mg, a targeted therapy used in certain types of lung cancer. It belongs to a class of medicines known as tyrosine kinase inhibitors (TKIs), specifically designed to block abnormal proteins that help cancer cells grow and spread. This Lorlatinib tablet is commonly prescribed for patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) that tests positive for an abnormal gene called ALK (anaplastic lymphoma kinase). By targeting this genetic alteration, LuciLorla 100 mg Tablet plays an important role in modern, precision-based oncology care. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, Lorlatinib works in a more focused way. It is typically used when cancer has progressed despite earlier ALK inhibitor treatments or as directed by an oncologist

Benefits

Key clinically relevant benefits of LuciLorla 100 mg Tablet include:

• Targets ALK gene alterations driving cancer growth

• Designed for patients with resistant or progressive ALK-positive NSCLC

• Demonstrated activity in metastatic disease, including brain metastases

• Oral tablet formulation for convenient daily dosing

• Precision-based therapy guided by molecular testing

These benefits are based on clinical research evaluating Lorlatinib in advanced ALK-positive lung cancer. Treatment outcomes vary depending on individual patient factors.

Indications and Usage

LuciLorla 100 mg Tablet (Lorlatinib 100mg) is indicated for:

• Treatment of ALK-positive non-small cell lung cancer (NSCLC)

• Patients with advanced or metastatic disease

• Patients whose cancer has progressed after treatment with one or more prior ALK inhibitors

• Situations where an oncologist determines Lorlatinib is clinically appropriate based on tumor genetics

Lorlatinib is specifically approved for ALK-positive lung cancer treatment, meaning it is effective only when cancer cells carry the ALK gene rearrangement. Testing for ALK mutation is required before starting therapy.

It is not used for all lung cancer types and should only be prescribed after proper diagnostic confirmation.

How it Works

Lorlatinib 100mg works by blocking a specific abnormal protein called ALK (anaplastic lymphoma kinase).

In some lung cancers, a genetic change causes the ALK protein to become overactive. This abnormal activity sends continuous growth signals to cancer cells, helping them multiply and survive.

LuciLorla 100 mg Tablet acts as an ALK tyrosine kinase inhibitor. It attaches to the altered ALK protein and blocks its signaling pathway. As a result:

• Cancer cell growth slows down

• Tumor progression may be controlled

• Spread of cancer cells may be reduced

Because it targets a specific genetic mutation, Lorlatinib tablet is considered a form of targeted therapy rather than traditional chemotherapy.

Dosage & Administration

• General dosing information (for reference only):

  • Standard recommended dose: 100 mg orally, once daily.
  • Can be taken with or without food.
  • Tablets should be swallowed whole — do not crush, chew, or split.
  • If a dose is missed, take it as soon as you remember — unless the next dose is within 4 hours. Never double up doses.
  • Treatment continues until disease progression or unacceptable toxicity, as determined by your oncologist.

  Important: Dosage adjustments may be required based on side effects, organ function, or drug interactions. Your oncologist will determine the right dosing regimen for your specific situation. Do not alter your dose without medical guidance.

Side Effects

Like all anti-cancer medicines, Lorlatinib 100mg may cause side effects. Not every patient experiences them, and their severity can vary.

Common Side Effects

• Increased cholesterol or triglyceride levels

• Swelling of hands, feet, or face

• Weight gain

• Fatigue

• Mood changes or cognitive effects

• Peripheral neuropathy (tingling or numbness in hands or feet)

• Diarrhea or constipation

Serious Side Effects

• Severe central nervous system (CNS) effects such as confusion or personality changes

• Liver function abnormalities

• Severe lipid elevation

• Heart rhythm changes

• Lung inflammation (rare but serious)

Patients should undergo regular blood tests to monitor liver function and cholesterol levels during treatment.

Contact your healthcare provider immediately if you experience severe or unusual symptoms.

Warning and Precaution

Before starting LuciLorla 100 mg Tablet, inform your doctor about your complete medical history.

Pregnancy and Breastfeeding

• Lorlatinib may cause harm to an unborn baby.

• Effective contraception is required during treatment and for a specified period after stopping therapy.

• Breastfeeding is not recommended while taking this medicine.

Liver Function

Regular liver function monitoring is important, as Lorlatinib can affect liver enzymes.

Central Nervous System Effects

Some patients experience mood changes, memory issues, or speech difficulties. Inform your doctor if you notice any behavioral or neurological changes.

Cholesterol Elevation

Lorlatinib 100mg commonly increases cholesterol and triglyceride levels. Lipid levels should be checked before and during treatment.

Drug Interactions

Lorlatinib tablet may interact with:

• Strong CYP3A inhibitors or inducers

• Certain antifungal or antibiotic medicines

• Herbal supplements like St. John’s Wort

Always inform your oncologist about all medications and supplements you are taking.